Related Experiment Videos
Eosinophilic polymyositis induced by tranilast.
1Department of Dermatology, School of Medicine, University of Tokushima, Japan.
The Journal of Dermatology
|March 1, 1990
Summary
This case study reports the first instance of eosinophilic polymyositis in a patient treated with Tranilast, an asthma medication. The drug was identified as the likely cause of the patient's severe muscle inflammation and symptoms.
Area of Science:
- Clinical Medicine
- Pharmacology
- Neurology
Background:
- Asthma management often involves various pharmaceutical agents.
- Tranilast is an antiasthmatic drug used in treating allergic conditions.
- Polymyositis is an inflammatory condition affecting muscles.
Observation:
- A 38-year-old male asthma patient developed eosinophilic polymyositis after Tranilast administration.
- Symptoms included fever, rash, dysphagia, eosinophilia, elevated muscle enzymes, and ECG changes.
- Muscle biopsy revealed eosinophilic and lymphocytic infiltration.
Findings:
- Tranilast was identified as the causative agent for eosinophilic polymyositis.
- Drug rechallenge confirmed Tranilast's role, triggering rash, eosinophilia, and elevated muscle enzymes.
- This represents the first documented case of Tranilast-induced eosinophilic polymyositis.
Implications:
- Highlights a rare but serious adverse drug reaction to Tranilast.
- Emphasizes the importance of considering drug-induced causes in polymyositis diagnosis.
- Informs clinicians about potential risks associated with Tranilast therapy.